HER2 negative metastatic breast cancer
Clinical trials for HER2 negative metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HER2 negative metastatic breast cancer trials appear
Sign up with your email to follow new studies for HER2 negative metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for tough cancers
Disease control OngoingThis study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…
Matched conditions: HER2 NEGATIVE METASTATIC BREAST CANCER
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the best dose and see if the combo is safe. Veliparib may help carboplatin work better by stopping cancer cells from r…
Matched conditions: HER2 NEGATIVE METASTATIC BREAST CANCER
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC